Literature DB >> 18574320

Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity.

Rajinder Singh1, Jonathan G Ting, Yan Pan, Lay Kek Teh, Rusli Ismail, Chin Eng Ong.   

Abstract

The work described in this study aimed to express CYP2C8 wild-type and mutant proteins in bacterial expression system and to use the expressed proteins to investigate the structural and functional consequences of a reported allele CYP2C8(*)4 (carrying Ile264Met substitution) on protein activity. Ile264 was replaced by three different amino acids resulting in three mutant constructs, 2C8I264M, 2C8I264R and 2C8I264D. The presence of isoleucine at position 264 in CYP2C8 was found to be important for proper haem insertion and protein folding; whereas bulkier or charged residues were highly disruptive resulting in inactive proteins with minimum spectral and catalytic activities. This was evidenced from the low levels of Soret peak at 450 nm and negligible levels of tolbutamide methylhydroxylase activity. Kinetic study using paclitaxel indicated that all three mutants exhibited only 9.7 to 35.4% of the activity level observed in the wild-type. In addition, the mutants were more sensitive to proteinase K digestion, indicating a possible alteration of conformation. The combined effects of protein instability and compromised catalytic activity resulted in defective CYP2C8 protein which may have clinical implications in carriers of CYP2C8*4, particularly in terms of their capacity to clear potent drugs and their susceptibility to adverse drug reactions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18574320     DOI: 10.2133/dmpk.23.165

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  10 in total

1.  In vitro modulatory effects of flavonoids on human cytochrome P450 2C8 (CYP2C8).

Authors:  Chia Yong Pang; Joon Wah Mak; Rusli Ismail; Chin Eng Ong
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-04       Impact factor: 3.000

2.  Genetic markers in the EET metabolic pathway are associated with outcomes in patients with aneurysmal subarachnoid hemorrhage.

Authors:  Mark K Donnelly; Yvette P Conley; Elizabeth A Crago; Dianxu Ren; Paula R Sherwood; Jeffery R Balzer; Samuel M Poloyac
Journal:  J Cereb Blood Flow Metab       Date:  2014-11-12       Impact factor: 6.200

3.  Variability of CYP2C8 Polymorphisms in Three Jordanian Populations: Circassians, Chechens and Jordanian-Arabs.

Authors:  Sara Abudahab; Nancy Hakooz; Nuha Tobeh; Esraa Gogazeh; Munir Gharaibeh; Laith Al-Eitan; Malek Zihlif; Rana Dajani
Journal:  J Immigr Minor Health       Date:  2021-08-26

4.  Carbon-carbon bond cleavage in activation of the prodrug nabumetone.

Authors:  Fatbardha Varfaj; Siti N A Zulkifli; Hyoung-Goo Park; Victoria L Challinor; James J De Voss; Paul R Ortiz de Montellano
Journal:  Drug Metab Dispos       Date:  2014-02-28       Impact factor: 3.922

5.  The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

Authors:  Deepak Voora; Svati H Shah; Ivan Spasojevic; Shazia Ali; Carol R Reed; Benjamin A Salisbury; Geoffrey S Ginsburg
Journal:  J Am Coll Cardiol       Date:  2009-10-20       Impact factor: 24.094

Review 6.  PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.

Authors:  Christina L Aquilante; Mikko Niemi; Li Gong; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-12       Impact factor: 2.089

7.  Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.

Authors:  Thomas M Polasek; Geoffrey T Tucker; Michael J Sorich; Michael D Wiese; Titus Mohan; Amin Rostami-Hodjegan; Porntipa Korprasertthaworn; Vidya Perera; Andrew Rowland
Journal:  Br J Clin Pharmacol       Date:  2018-01-11       Impact factor: 4.335

8.  Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.

Authors:  Daniel L Hertz; Siddharth Roy; John Jack; Alison A Motsinger-Reif; Amy Drobish; L Scott Clark; Lisa A Carey; E Claire Dees; Howard L McLeod
Journal:  Breast Cancer Res Treat       Date:  2014-04-06       Impact factor: 4.872

9.  Global variation in CYP2C8-CYP2C9 functional haplotypes.

Authors:  William C Speed; Soonmo Peter Kang; David P Tuck; Lyndsay N Harris; Kenneth K Kidd
Journal:  Pharmacogenomics J       Date:  2009-04-21       Impact factor: 3.550

10.  Inhibitory potency of 8-methoxypsoralen on cytochrome P450 2A6 (CYP2A6) allelic variants CYP2A6 15, CYP2A6 16, CYP2A6 21 and CYP2A6 22: differential susceptibility due to different sequence locations of the mutations.

Authors:  Kai Hung Tiong; Nafees Ahemad Mohammed Yunus; Beow Chin Yiap; Eng Lai Tan; Rusli Ismail; Chin Eng Ong
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.